207 selected records with a cited source date in 2023, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT01524705 at 2026-07-30T19:03:45.487Z. Its registry update date was 2023-12-29, and PeptideScanner's reviewed identity mapping was exenatide.
DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2023-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 38098608 in Annals of medicine and surgery (2012) as Journal Article, Review, with publication-date metadata of 2023-11-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00868283 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-12-15, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.
DailyMed lists Structured Product Labeling version 3 for the reviewed Teriparatide label family with a published date of 2023-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217987 with status AP dated 2023-12-06, and names vasopressin among the application record's active ingredients.
PubMed lists PMID 38050530 in Cureus as Journal Article, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 210317 with status AP dated 2023-12-05, and names octreotide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide.
PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 1 for the reviewed Octreotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Ziconotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00818623 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00819156 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.
DailyMed lists Structured Product Labeling version 15 for the reviewed Abaloparatide label family with a published date of 2023-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04290429 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-11-29, and PeptideScanner's reviewed identity mapping was teduglutide.
DailyMed lists Structured Product Labeling version 6 for the reviewed Setmelanotide label family with a published date of 2023-11-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.
PubMed lists PMID 37774815 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2023-09-27 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
DailyMed lists Structured Product Labeling version 2 for the reviewed Teriparatide label family with a published date of 2023-11-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216075 with status AP dated 2023-11-16, and names ganirelix acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208569 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211097 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 10 for the reviewed Vosoritide label family with a published date of 2023-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PubMed lists PMID 32927756 in Vaccines as Journal Article, Review, with publication-date metadata of 2020-09-10 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 32863841 in Drugs in context as Journal Article, with publication-date metadata of 2020-08-12 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 28003770 in The application of clinical genetics as Review, Journal Article, with publication-date metadata of 2016-12-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37930495 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2023-11-06 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 33305109 in Kidney international reports as Journal Article, with publication-date metadata of 2020-09-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00819247 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-09, and PeptideScanner's reviewed identity mapping was degarelix.
The official Drugs@FDA dataset lists original submission 1 for NDA 217806 with status AP dated 2023-11-08, and names tirzepatide among the application record's active ingredients.
PubMed lists PMID 37928358 in Frontiers in pediatrics as Journal Article, Review, with publication-date metadata of 2023-10-19 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37746717 in Circulation as Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 35518928 in Frontiers in endocrinology as Case Reports, Review, Journal Article, with publication-date metadata of 2022-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37830186 in The Journal of organic chemistry as Journal Article, with publication-date metadata of 2023-10-13 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
PubMed lists PMID 37896245 in Pharmaceutics as Journal Article, with publication-date metadata of 2023-10-18 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide.
PubMed lists PMID 37887193 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-09-28 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT02150954 at 2026-11-16T00:59:19.138Z. Its registry update date was 2023-10-26, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT05199714 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-25, and PeptideScanner's reviewed identity mapping was pramlintide.
PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 31815212 in ACS omega as Journal Article, with publication-date metadata of 2019-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 49 for the reviewed Dulaglutide label family with a published date of 2023-10-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 216834 with status AP dated 2023-10-17, and names zilucoplan sodium among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 7 for the reviewed Afamelanotide label family with a published date of 2023-10-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 18 for the reviewed Lixisenatide label family with a published date of 2023-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 37114900 in International journal of rheumatic diseases as Review, Case Reports, Journal Article, with publication-date metadata of 2023-04-28 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 30425276 in Scientific reports as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2018-11-13 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations.
PeptideScanner retained ClinicalTrials.gov record NCT03426761 at 2026-11-15T22:01:45.056Z. Its registry update date was 2023-10-03, and PeptideScanner's reviewed identity mapping was daptomycin.
The official Drugs@FDA dataset lists original submission 1 for NDA 217569 with status AP dated 2023-09-29, and names vasopressin among the application record's active ingredients.
PubMed lists PMID 32433845 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 32433846 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 32433847 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 30302125 in Therapeutic advances in gastroenterology as Journal Article, with publication-date metadata of 2018-10-03 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03960437 at 2026-11-15T22:07:29.454Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.
DailyMed lists Structured Product Labeling version 33 for the reviewed Linaclotide label family with a published date of 2023-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT02896192 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was setmelanotide.
DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2023-09-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.
PubMed lists PMID 37041092 in Journal of pediatric surgery as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05407597 at 2026-11-15T22:04:12.435Z. Its registry update date was 2023-09-07, and PeptideScanner's reviewed identity mapping was icatibant.
PubMed lists PMID 37671395 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2023-19013, attributed to FDA and its parent HHS department, on 2023-09-05. Its official title is “Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.
PubMed lists PMID 37651297 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PubMed lists PMID 37649925 in Cureus as Journal Article, Review, with publication-date metadata of 2023-08-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 1 for the reviewed Leuprolide label family with a published date of 2023-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 37646058 in Advanced pharmaceutical bulletin as Journal Article, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.
PubMed lists PMID 37522695 in European review for medical and pharmacological sciences as Review, Case Reports, Journal Article, with publication-date metadata of 2023-07 (month precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PubMed lists PMID 36636586 in JIMD reports as Journal Article, with publication-date metadata of 2022-09-21 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213521 with status AP dated 2023-08-14, and names icatibant acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213966 with status AP dated 2023-08-07, and names daptomycin among the application record's active ingredients.
The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT03389412 at 2026-11-16T01:33:21.554Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide.
PubMed lists PMID 37513919 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-07-15 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT03331289 at 2026-07-30T19:10:42.713Z. Its registry update date was 2023-07-24, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03169166 at 2026-11-15T21:49:16.513Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT02981069 at 2026-07-30T19:10:42.759Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was exenatide.
PubMed lists PMID 37455491 in Pharmacology research & perspectives as Journal Article, with publication-date metadata of 2023-08 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37195551 in PharmacoEconomics - open as Journal Article, Review, with publication-date metadata of 2023-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01364584 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-12, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00571727 at 2026-11-16T17:35:13.282Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT03525613 at 2026-11-16T01:37:14.654Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT02527200 at 2026-07-30T19:10:42.748Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was liraglutide.
PubMed lists PMID 37120679 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-29 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00427349 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-05, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03043664 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01841359 at 2026-07-30T19:11:49.725Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was pramlintide.
DailyMed lists Structured Product Labeling version 13 for the reviewed Abaloparatide label family with a published date of 2023-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216839 with status AP dated 2023-06-22, and names octreotide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 32 for the reviewed Linaclotide label family with a published date of 2023-06-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00003057 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-18, and PeptideScanner's reviewed identity mapping was octreotide.
PubMed lists PMID 37270286 in The American journal of clinical nutrition as Editorial, Comment, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37270289 in The American journal of clinical nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00003283 at 2026-07-30T19:11:49.727Z. Its registry update date was 2023-06-15, and PeptideScanner's reviewed identity mapping was octreotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216807 with status AP dated 2023-06-13, and names octreotide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02431325 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-06-12, and PeptideScanner's reviewed identity mapping was teduglutide.
PubMed lists PMID 36824008 in Diabetes & metabolism journal as Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-24 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT04652479 at 2026-11-16T01:46:44.871Z. Its registry update date was 2023-06-09, and PeptideScanner's reviewed identity mapping was avexitide.
PeptideScanner retained ClinicalTrials.gov record NCT04605861 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-07, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03404661 at 2026-11-16T01:34:15.953Z. Its registry update date was 2023-06-06, and PeptideScanner's reviewed identity mapping was secretin.
PubMed lists PMID 37259853 in Immunotherapy as Journal Article, Review, with publication-date metadata of 2023-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213206 with status AP dated 2023-05-26, and names vasopressin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02333565 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-25, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02384122 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-24, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03287960 at 2026-07-30T19:13:03.752Z. Its registry update date was 2023-05-23, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03572088 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-22, and PeptideScanner's reviewed identity mapping was terlipressin.
PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2023-10710, attributed to FDA and its parent HHS department, on 2023-05-19. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.
DailyMed lists Structured Product Labeling version 6 for the reviewed Afamelanotide label family with a published date of 2023-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03072147 at 2026-07-30T19:13:03.748Z. Its registry update date was 2023-05-12, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01779362 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04859322 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02025179 at 2026-07-30T19:13:03.751Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03822091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-09, and PeptideScanner's reviewed identity mapping was terlipressin.
PubMed lists PMID 36870402 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2023-03-02 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 31 for the reviewed Linaclotide label family with a published date of 2023-05-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03664180 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-05-03, and PeptideScanner's reviewed identity mapping was bivalirudin.
PubMed lists PMID 37111596 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2023-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 48 for the reviewed Dulaglutide label family with a published date of 2023-05-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01416649 at 2026-07-30T19:14:02.187Z. Its registry update date was 2023-04-26, and PeptideScanner's reviewed identity mapping was exenatide.
PubMed lists PMID 36194483 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Systematic Review, Meta-Analysis, Journal Article, with publication-date metadata of 2022-04-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05807503 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PubMed lists PMID 25070319 in The Journal of clinical endocrinology and metabolism as Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2014-07-29 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT04962503 at 2026-07-30T19:14:02.188Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT02867267 at 2026-11-15T22:10:40.222Z. Its registry update date was 2023-04-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04416282 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-04-06, and PeptideScanner's reviewed identity mapping was terlipressin.
DailyMed lists Structured Product Labeling version 14 for the reviewed Plecanatide label family with a published date of 2023-04-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00432172 at 2026-11-15T21:50:32.222Z. Its registry update date was 2023-04-03, and PeptideScanner's reviewed identity mapping was goserelin.
PubMed lists PMID 36999064 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2023-03-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36858006 in Journal of pharmaceutical and biomedical analysis as Case Reports, Journal Article, Review, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36979317 in Brain sciences as Journal Article, Review, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36982519 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2023-03-13 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.
PeptideScanner retained ClinicalTrials.gov record NCT04172987 at 2026-07-30T19:15:14.513Z. Its registry update date was 2023-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 35735062 in Journal of clinical pharmacy and therapeutics as Journal Article, Review, with publication-date metadata of 2022-06-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 4 for the reviewed Ziconotide label family with a published date of 2023-03-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03940742 at 2026-07-30T19:15:14.510Z. Its registry update date was 2023-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216904 with status AP dated 2023-03-20, and names desmopressin acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT03596164 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-03-15, and PeptideScanner's reviewed identity mapping was teduglutide.
PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 13 for the reviewed Plecanatide label family with a published date of 2023-03-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients.
PubMed lists PMID 36611532 in Healthcare (Basel, Switzerland) as Journal Article, with publication-date metadata of 2022-12-26 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 12 for the reviewed Plecanatide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.
The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215658 with status AP dated 2023-02-28, and names ganirelix acetate among the application record's active ingredients.
PubMed lists PMID 36844198 in Frontiers in medicine as Journal Article, with publication-date metadata of 2023-02-08 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 36565004 in Alimentary pharmacology & therapeutics as Editorial, Comment, with publication-date metadata of 2023-01 (month precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 14 for the reviewed Pramlintide label family with a published date of 2023-02-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.
The official Drugs@FDA dataset lists original submission 1 for NDA 217171 with status AP dated 2023-02-17, and names pegcetacoplan among the application record's active ingredients.
The Federal Register published notice 2023-03389, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
PubMed lists PMID 36452455 in Frontiers in molecular biosciences as Journal Article, Review, with publication-date metadata of 2022-11-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide.
PubMed lists PMID 35839450 in Blood as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-09-08 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide.
PubMed lists PMID 36227704 in The Journal of antimicrobial chemotherapy as Systematic Review, Journal Article, with publication-date metadata of 2022-12-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209611 with status AP dated 2023-02-07, and names linaclotide among the application record's active ingredients.
The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PubMed lists PMID 36704426 in Research in pharmaceutical sciences as Journal Article, with publication-date metadata of 2022-10-29 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03318393 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-01-31, and PeptideScanner's reviewed identity mapping was bivalirudin.
The official Drugs@FDA dataset lists original submission 1 for NDA 217415 with status AP dated 2023-01-30, and names daptomycin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.